



February 26, 2026

Company: KYORIN Pharmaceutical Co., Ltd.  
Representative: Yutaka Ogihara  
Representative Director, President and CEO  
(Security Code: 4569, TSE Prime.)  
Contact: Shota Kikuchi  
Director, Corporate Planning  
Telephone: 03-6374-9702

## Notice Regarding the Introduction of a Mandate-Based Corporate Officer System and Changes in Corporate Officers

KYORIN Pharmaceutical Co., Ltd. hereby announced that at a Board of Directors meeting held today, the Company resolved to introduce a Mandate-Based Corporate Officer System and approved the following executive appointments.

### 1. Introduction of the Mandate-Based Corporate Officer System

#### (1) Purpose of the Introduction

From the perspective of strengthening corporate governance, the Company will introduce a Mandate-Based Corporate Officer System in addition to the existing Employment-Based System. The objective is to further separate decision-making and supervisory functions from business execution functions, thereby enhancing management soundness and transparency.

#### (2) Overview of the System

- Mandate-Based Corporate Officers apply to the rank of Managing Corporate Officer and higher. Employment-Based Corporate Officers apply to the rank of Corporate Officers.
- Executive Directors may concurrently serve as Corporate Officers.

#### (3) Implementation Date

April 1, 2026

## 2. Personnel Changes (Effective April 1, 2026)

### (1) Changes Related to Executive Directors

New Title	Former Title	Ongoing Roles	Name
President and CEO		Representative Director, President and CEO, in charge of Auditing	Yutaka Ogihara
Managing Corporate Officer		Executive Director CMO, in charge of Quality Assurance & Reliability HQs and SCM. Chairman of KYORIN Pharmaceutical Group Facilities Co., Ltd.	Michiro Onota
Managing Corporate Officer		Executive Director CFO & CStO, Director of Corporate Planning, in charge of Finance & Accounting and Innovation Promoting	Yasuji Kurose

### (2) Changes Related to Mandate-Based Corporate Officers

New Title	Former Title	Ongoing Roles	Name
Managing Corporate Officer	Corporate Officer	CBDO, Senior Director of Business Development HQs	Takaaki Kaji
Managing Corporate Officer	Corporate Officer	CCO, Senior Director of Sales & Marketing HQs, in charge of IT Solution and In Vitro Diagnostics Business	Noriaki Tamura
Managing Corporate Officer	Corporate Officer	CSO, Senior Director of Discovery Research HQs, in charge of Intellectual Property	Junichi Ishiyama
Managing Corporate Officer	Corporate Officer	CHRO, Director of General Affairs, in charge of Human Resources and Legal & Compliance	Kiyoo Uehara

### (3) Changes Related to Employment-Based Corporate Officers

#### a. Newly Appointed Corporate Officers

New Title	Former Title	Ongoing Roles	Name
Corporate Officer, Senior Director of Quality Assurance & Reliability HQs	Associate Director of Quality Assurance, Quality Assurance & Reliability HQs		Hiroki Usui

b. Changes in Assignments and Responsibilities

New Title	Former Title	Ongoing Roles	Name
Director of Innovation Promoting	Director of Product Strategy	Corporate Officer	Kimiya Masada

Note: Due to the organizational restructuring effective April 1, 2026, the SCM HQs will be reorganized into the SCM (discontinuing the division-based system), and the Product Strategy will be renamed the Innovation Promoting.